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Abstract
Low serum concentrations of antibodies directed against the toxins TcdA and TcdB have been associated with a higher risk of recurrence of
Clostridium difficile infection (CDI) after successful antibiotic treatment. However, there are conflicting reports. Herein, we compared serum
levels of antibodies of patients with a single episode of CDI with those of patients who subsequently suffered a recurrence. We used a
serum bank from patients who received an experimental whey protein product following successful antibiotic treatment for CDI. We
determined levels of IgA and IgG directed against TcdA, TcdB and non-toxin cell surface antigens in serum collected directly and 3 weeks
after completing a 10-day course of antibiotic treatment for CDI. We also developed an objective flow cytometry-based assay to determine
the proportion of cells exhibiting cytopathic effect after exposure to TcdB. Using this method, we measured the TcdB-neutralizing capacity
of sera. We compared the results for patients without a subsequent recurrence with those of patients who suffered a recurrence within
60 days after completing the antibiotic treatment. Advanced age, comorbidity other than immunocompromised state and low serum levels
of anti-TcdA and anti-TcdB antibodies were associated with recurrence, whereas serum levels of antibodies directed against cell surface
antigens were not. Serum TcdB-neutralizing capacity, which correlated only weakly with serum IgG anti-TcdB, was not significantly
associated with recurrence.
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Introduction
Clostridium difficile infection (CDI) is an important problem in
healthcare facilities. Spores of this bacterium are ingested and
bacteria may colonize the gut after germination. Colonization
of the gut may lead to carriage or disease, which ranges from
mild self-limiting diarrhoea to fulminant life-threatening colitis.
Mild disease may subside after withdrawal of antibiotics.
Moderate and severe disease usually respond to oral metro-
nidazole, glycopeptides, or fidaxomicin, but often recur.
Factors associated with the course of the disease include
recent exposure to antibiotics, virulence of the C. difficile
strain, advanced age, severe comorbidity, the use of proton
pump inhibitors and the presence of antibodies directed
against the toxins TcdA and TcdB and/or other antigens [1].
However, the role of humoral immunity in CDI is unclear
because of conflicting reports on the association between the
humoral immune response and disease outcome [2–11].
Important issues include the type of antibodies (secretory
IgA or IgG) involved, whether serum antibodies reflect
mucosal immunity in the gut, whether TcdA or TcdB must
be neutralized, which toxin epitope is the most important one,
and whether antibodies directed against antigens other than
toxin matter.
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To investigate the possible relationship between the
humoral immune response and the outcome of CDI, we
compared serum levels of IgA and IgG directed against TcdA,
TcdB and non-toxin cell surface antigens of patients with a
single episode with those of patients with a subsequent CDI
recurrence.
Methods
Serum samples
Serum samples were taken during a prospective cohort study
[12] into the safety and preliminary efficacy of a whey protein
concentrate made from the milk of cows immunized against
C. difficile to prevent recurrences after successful antibiotic
treatment of CDI [13]. CDI was suspected clinically and
confirmed by a positive faecal toxin assay and culture. Patient
data registered on enrolment included age, sex, disease
severity and chronic comorbidity according to the Acute
Physiology, Age and Chronic Health Evaluation (APACHE) II
prognostic system [14], previous episodes of CDI, and
antibiotic treatment before starting the whey protein concen-
trate. After completion of 10 days of standard antibiotic
therapy and reaching clinical remission of CDI, participating
patients received this whey protein concentrate orally for
2 weeks with a follow-up period of 60 days. Outcome
measures were CDI recurrences. Recurrence was declared if
the patient reported looser stools according to a three-grade
visual scale, in comparison to the day before and an increase in
stool frequency for two consecutive days, or a single day with
an increase of three or more stools, or any day with passage of
more than six stools/day, and a positive C. difficile toxin stool
test (Vidas, BioMerieux, Marcy l’Etoile, France) and culture.
Among cultured strains, those strains belonging to PCR-rib-
otype 027 were identified as described previously [15]. Serum
samples were taken from these patients on the day they
started on the whey protein concentrate (i.e. after 10 days of
antibiotic therapy), and a second time 18–21 days later.
ELISA for the determination of serum anti-TcdA and
anti-TcdB IgA and IgG
Wells of flat-bottom 96-well high-binding plates (Greiner
Bio-One, Frickenhausen, Germany) were incubated with
100 lL per well of toxin in a 100 mM carbonate buffer (pH
9.6) overnight at 4°C. For the IgA anti-toxin assays the wells
were coated with 1.5 mg/L of TdA (Mucovax, Leiden, the
Netherlands) or 1.0 mg/L of TcdB (kindly provided by Dr H.
Feng, Tufts University Cummings School of Veterinary Medi-
cine, Grafton, MA, USA) and for the IgG assays wells were
coated with 1.0 mg/L of TcdA or TcdB. The plates were then
washed three times with PBS (pH 7.4) as well as between every
two incubation steps. Next, the plates were incubated with
200 lL of blocking buffer (2% weight/volume (wt/v) gelatine in
PBS containing 0.05% v/v Tween-20) for 1 h at 37°C. There-
after, serial dilutions of serum samples diluted in 0.2% wt/v
gelatine in PBSwith 0.05% v/v Tween-20were transferred to the
plate (100 lL/well) and incubated for 90 min at 37°C. All serum
samples were tested in duplicate. The dilution buffer was used as
a negative control. Subsequently, the plates were incubated with
100 lL of 4000 9 diluted polyclonal rabbit anti-human IgA
antibodies conjugated with horseradish peroxidase (HRP) or
6000 9 diluted HRP-conjugated polyclonal rabbit anti-human
IgG antibodies (DakoCytomation, Glostrup, Denmark) for
90 min at 37°C. Lastly, the plates were incubated with 2.5 mg/
mL of filtered 2,20-azoni-bis(3-ethylbenzothiazoline-6-sulphonic
acid) (Roche, Basel, Switzerland) in substrate buffer (47.2% of
100 mM citric acid and 52.8% of 100 mM Na2HPO4; pH 4.2;
100 lL/well) and 0.015% v/v H2O2 for 30 min at 37°C. The
absorbance was measured at 405 nm. For standardization,
serum samples with high levels of anti-TcdA immunoglobulins
(IgA or IgG) were pooled, assigned an arbitrary value of 10 000
units (U) per mL, and used in all assays as standard.
ELISA for the determination of serum IgG directed against
other antigens
The following non-toxin antigens were prepared from PCR
ribotypes 001 and 027 as previously described: an EDTA
extract representing the entire cell surface layer, a guanidine
hydrochloride extracted S-layer protein, an aqueous phe-
nol-extracted lipoteichoic acid analogue (only from ribotype
001) [16] and whole flagella (mechanically sheared and purified
on a caesium chloride gradient) as described by Hancock and
Poxton [17]. ELISAs for IgG levels to these antigens were
performed as described by Sanchez-Hurtado and Poxton [16].
Flow cytometric assay to determine the capacity of serum to
neutralize TcdB
We developed an objective method to determine the level of
TcdB-neutralizing antibodies in sera. Briefly, 3T3 cells, a
spontaneously immortalized cell line derived from embryonic
mouse fibroblasts, were cultured in a 96-well tissue culture plate
until a semi-confluent monolayer was formed. Serial dilutions of
TcdB in culture medium were pre-incubated 1 : 1 with fourfold
diluted heat-inactivated patient serum for 1 h at room temper-
ature on a microplate shaker. Next, we incubated these
mixtures of toxin and serum (100 lL per well) with the cells
at 37°C for 1 h. Heat-inactivated pooled human serum (Lonza,
Basel, Switzerland) was used as a standard. Toxin diluted in
culture medium to a concentration of 50 ng/mL was used as a
positive control and culture medium only as a negative control.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1323–1328
1324 Clinical Microbiology and Infection, Volume 20 Number 12, December 2014 CMI
After washings, the cells were cultured overnight and the degree
of cytopathic effect (CPE) was assessed microscopically. Next,
we removed the cells from the wells by mechanically detaching
them and then examined approximately 10 000 cells per sample
on a FACSCalibur (Becton and Dickinson, La Jolla, CA, USA).
Results are expressed as the mean fluorescence intensity (MFI)
in arbitrary units. The MFI of the cell population was used as a
measure of the proportion of cells showing CPE. The MFI’s for
the positive control well and the negative control well were
considered to characterize a cell population with maximumCPE
and an unaffected cell population, respectively. For practical
purposes, the mean of these MFI values was considered to
represent 50% CPE. The MFI for the toxin dilution pre-incu-
bated with patient serum that resulted in 50% CPE was divided
by the value for the toxin dilution pre-incubated with standard
serum resulting in 50% CPE to yield a standardized measure of
the toxin-neutralizing capacity (Table 1).
Statistical analysis
The distributions of continuous variables were compared with
a Mann–Whitney U-test and proportions with the chi-square
test. The strength of the relationship between two continuous
variables was estimated by Kendall’s s-b. Continuous variables
were dichotomized using the median for the entire population
as a cut-off. For the association between dichotomized
variables and recurrence, OR with 95% CI were calculated.
To examine the presence of confounding, categorical variables
with a strong and clear association (OR >2 and p <0.2) with
recurrence were introduced into a multivariate logistic
regression model. IBM SPSS Statistics 20.0 (IBM Corporation,
Armonk, NY, USA) software was used for the calculations.
Results
Of 120 CDI patients whose data were present in the database,
16 (13.3%) suffered a toxin-confirmed recurrence. Unfortu-
nately, for some patients, the amount of serum was limited, so
that not all assays could be performed. Table 2 shows patient
characteristics. Advanced age and severe comorbidity were
predictors of recurrence. However, immunocompromised
state was not. Treatment with vancomycin was non-signifi-
cantly associated with subsequent recurrence, probably
reflecting more severe CDI for which treatment with vanco-
mycin was preferred over metronidazole.
Table 3 shows IgA and IgG anti-TcdA and anti-TcdB
antibody levels and TcdB-neutralizing levels in sera from
patients with and those without recurrence. Low serum levels
of IgA anti-TcdA and IgG anti-TcdB 3 weeks after completing
10 days of antibiotic treatment for CDI were most clearly
associated with recurrence, as well as a decrease in serum IgG
anti-TcdA during this time period. Some of these associations
reached statistical significance. Interestingly, serum levels of
anti-toxin A/B antibodies decreased in many patients during
the 3 weeks after antibiotic treatment.
TABLE 1. Comparison of the flow cytometric and light
microscopical assessment of the toxic effect of TcdB on 3T3
cells
Treatment MFI Light microscopy
TcdB 50 ng/mL 310 AU All cells showing CPE
TcdB 8.3 ng/mL with
patient’s serum
332 AU More cells showing CPE than
unaffected cells
TcdB 5.6 ng/mL with
patient’s serum
366 AU Cells showing CPE mixed with
unaffected cells
TcdB 3.7 ng/mL with
patient’s serum
436 AU Cells showing CPE mixed with
unaffected cells
TcdB 2.5 ng/mL with
patient’s serum
481 AU More unaffected cells than cells
showing CPE
Medium alone 508 AU No cells showing CPE
MFI = median fluorescence activity. AU = arbitrary units. CPE = cytopathic effect
TABLE 2. Characteristics of CDI patients after completion
of 10 days of antibiotic treatment
Recurrence No recurrence
pn Result n Result
Epidemiological characteristics:
Age (median and IQR) 15 77 (73–84) 99 69 (52–79) 0.057
Age >73 years (%) 15 80 99 46 0.013
Male sex (%) 16 38 103 50 0.371
Liver cirrhosis with
portal hypertension*
(%)
16 0 100 10 0.186
Heart failure NYHA
class IV (%)
16 31 99 18 0.225
Severe pulmonary
disease* (%)
16 44 98 28 0.189
Receiving chronic
dialysis (%)
16 13 100 6 0.341
Immunocompromised*
(%)
16 25 98 34 0.492
Any of the above
comorbidities (%)
16 81 98 56 0.057
Any of the above
comorbidities without
immunocompromised
status (%)
16 75 98 43 0.017
Recurrent CDI episode
versus first episode (%)
16 44 102 40 0.788
Number of previous CDI
episodes (median
and IQR)
16 0 (0–1) 102 0 (0–1) 0.839
Recent episode treated
with metronidazole (%)
16 31 102 49 0.185
Recent episode treated
with vancomycin (%)
16 69 102 48 0.123
Clinical, haematological, biochemical and microbiological characteristics:
Leucocyte count (109/L)
(median and IQR)
15 7.6 (6.1–15.3) 72 9.0 (6.6–13.3) 0.536
Creatinine (lmol/L)
(median and IQR)
16 83 (61–124) 101 82 (62–127) 0.949
Serum albumin (g/L)
(median and IQR)
13 38 (27–39) 66 31 (23–37) 0.092
APACHE II score
(median and IQR)
12 2 (0–4) 57 1 (0–3) 0.380
Episode of CDI
caused by PCR
ribotype 027 (%)
12 50 60 28 0.142
*According to the Chronic Health Points score of APACHE II.
CDI, Clostridium difficile infection; n, number of patients for whom information was
available; IQR, interquartile range; Results printed in boldface have reached
statistical significance (p <0.05).
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Low serum TcdB-neutralizing capacity was not a predictor
of recurrence, although none of the patients with a higher
serum neutralizing capacity than the reference serum suffered
a recurrence. There was no correlation between anti-TcdB
IgA level in serum and its capacity to neutralize TcdB (day 0:
correlation coefficient (r) = 0.155, p 0.185; day 18: r = 0.185,
p 0.129) and only a weak correlation between anti-TcdB IgG
level in serum and its capacity to neutralize TcdB (day 0:
r = 0.253, p 0.036; day 18: r = 0.309, p 0.011).
Serum levels of IgG directed against any of the non-toxin
cell-surface antigens after antibiotic treatment did not differ
between patients with subsequent recurrence and those
without subsequent recurrence (data not shown).
Antibody levels and neutralizing capacity were dichoto-
mized using the median of the entire population of patients as a
cut-off. Odds ratios for the association with recurrence were
calculated (Table 4). To investigate possible confounding, the
odds ratios for these dichotomized antibody levels were
corrected for age over 73 years and the presence of severe
comorbidity. Serum levels of IgA anti-TcdB directly after
antibiotic treatment and IgG directed against both toxins
3 weeks later and a decrease in serum IgG anti-TcdA were
associated most strongly with recurrence.
Discussion
The main findings of this study in patients with CDI are that
advanced age, comorbidity and low serum levels of antibodies
directed against TcdA and TcdB were associated with
recurrence, whereas serum levels of antibodies directed
against cell surface antigens were not.
The strong points of this study pertain to the study
protocol and analytic methods. First, the data derive from a
prospective study in which patient characteristics and sera
were collected according to a standardized protocol. Second,
blood was collected at two time-points, which allowed for
the analysis of the dynamics of antibody levels. Third,
standardized ELISAs for antibodies against toxins A and B
and an objective assay for toxin-neutralization capacity of
sera were developed. Clostridial toxin neutralization assays
are commonly based on microscopic assessment of CPE on
cells. In these assays, a cell population showing 50% CPE is
used to compare the rate of toxin neutralization. Because
there are grades of CPE (e.g. loss of length and number of
cell processes, gradual rounding of cells), the proportion of
cells showing CPE may vary per visual field and certain
unaffected cells that are not fully attached to the surface may
appear to show CPE, we felt that assessing 50% CPE
microscopically is subjective. Unfortunately, the relatively
small number of patients with recurrence and the fact that all
patients were treated with a whey protein concentrate
containing antibodies against C. difficile and its toxins may
have compromised statistical power to detect differences
between CDI patients with recurrence and those without
recurrence. Moreover, for some patients, the amount of
serum was insufficient to perform all assays. Another
limitation of the present study pertains to quantification of
antibody levels in sera instead of faecal samples. Currently, it
is not known to what extent serum antibody levels reflect
TABLE 3. Antibodies against Clostridum difficile antigens in serum of CDI patients with and those without recurrence
Recurrence No recurrence
pn Median IQR n Median IQR
Day 0:
Serum IgA anti-TcdA (arbitrary units) 14 327 128–576 74 477 197–1027 0.133
Serum IgG anti-TcdA (arbitrary units) 14 580 162–1286 75 350 166–1430 0.696
Serum IgA anti-TcdB (arbitrary units) 15 986 659–1155 67 1603 665–2894 0.067
Serum IgG anti-TcdB (arbitrary units) 15 810 390–1423 65 974 537–3904 0.392
Serum TcdB-neutralizing capacity
(proportion of that of reference
pooled serum)
7 0.42 0.30–0.85 33 0.45 0.40–1.15 0.485
Day 18–21:
Serum IgA anti-TcdA (arbitrary units) 14 183 0–389 76 423 198–1255 0.009
Serum IgG anti-TcdA (arbitrary units) 14 237 0–815 75 486 186–1660 0.121
Serum IgA anti-TcdB (arbitrary units) 11 835 387–1001 68 1280 561–2551 0.133
Serum IgG anti-TcdB (arbitrary units) 11 446 224–892 68 954 527–2932 0.030
Serum TcdB-neutralizing capacity
(proportion of that of reference
pooled serum)
4 0.46 0.37–0.61 33 0.60 0.40–1.10 0.354
Increase between day 0 and day 18–21:
Serum IgA anti-TcdA (arbitrary units) 14 73 372–2 74 28 297–66 0.620
Serum IgG anti-TcdA (arbitrary units) 14 175 795–20 74 0 92–263 0.007
Serum IgA anti-TcdB (arbitrary units) 11 36 711–263 44 451 1485–83 0.323
Serum IgG anti-TcdB (arbitrary units) 11 568 2022–99 43 358 1007–263 0.499
CDI, Clostridium difficile infection; n, number of patients for whom information was available; IQR, interquartile range; Day 0, the day after completing 10 days of antibiotic
treatment. Results printed in boldface have reached statistical significance (p <0.05).
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mucosal immunity, which is probably the relevant part of the
immune system given that CDI is not an invasive infection.
Finally, the analysis of toxin-neutralizing capacity of the sera
was limited to TcdB, as this toxin was considered the most
important one in the pathogenesis of CDI according to
scientific consensus at the time of experimentation.
Several studies have found associations between humoral
immunity and the clinical course of CDI. For instance, it has
been reported that serum IgG directed against TcdA, and less
convincingly, IgG directed against TcdB and other antigens [5]
as well as all classes of antibodies directed against whole cell
C. difficile [8] are associated with disease instead of carriage.
Warny et al. [11] found low serum IgG and faecal sIgA directed
against TcdA to be associated with a longer duration of illness
and a higher risk of recurrence. Others reported that low
levels of IgM directed against various antigens and low levels of
IgG directed against TcdA, but not TcdB or other antigens,
predict recurrence [6]. Aronsson et al. [2] identified low
serum IgG directed against TcdB to be a better predictor of
recurrence than low serum IgG directed against TcdA. Leav
et al. [7] found IgG directed against the receptor-binding
domain of TcdB and to a lesser extent that of TcdA, but not
against whole toxins, and Drudy et al. [3] reported IgM
directed against surface-layer proteins to predict recurrence.
By contrast, Johnson et al. [4] and Sanchez-Hurtado et al. [9]
found that humoral immune responses did not influence the
clinical course of CDI. Recently, Solomon et al. [10] reported
no correlation between serum IgG anti-TcdA and IgG
anti-TcdB and recurrence, but did find a relationship between
low levels of these antibodies and 30-day all-cause mortality,
most of which was at least partly attributed to CDI.
Several findings raise the possibility that serum anti-toxin
antibody levels are not causally related with recurrences. In
this study, the serum antitoxin antibody levels in most of the
patients with and without recurrence decreased during the
first 3 weeks after completion of the antibiotic course. In
addition, immunocompromised state was not associated with
recurrence. Furthermore, in contrast to serum antibodies
directed against toxins, the TcdB-neutralizing capacity of sera
did not predict recurrence. It could be that low serum
antibody levels are caused by faecal protein loss from a
severely inflamed colonic mucosa. The severity of colonic
inflammation may itself be associated with the risk of
recurrence. The facts that several studies have found hypo-al-
buminaemia to predict recurrence [18] and that our study
found patients with subsequent recurrence to recover less
from hypo-albuminaemia than patients without recurrence
(data not shown) support this hypothesis. On the other hand,
there are arguments against this hypothesis. Low levels of
antibody against non-toxin, cell-surface antigens were not
associated with recurrence. Moreover, the administration of
parenteral monoclonal antibodies against the C-terminus of
TcdA and TcdB has been found to prevent recurrences [19].
In conclusion, low serum anti-TcdA and anti-TcdB antibod-
ies are associated with a higher risk of recurrence. However,
further studies into the humoral immune responses in CDI,
simultaneously measuring serum and faecal antibody levels at
several time points, as well as measuring faecal protein loss
TABLE 4. Dichotomized variables as predictors of CDI recurrence
Recurrence
No
recurrence
OR 95% CI aOR 95% CIn % n %
Epidemiological characteristics:
Age >73 years 15 80 99 46 4.80 1.28–18
Comorbidity other than
immunocompromised status
16 75 98 43 4.00 1.21–13
Antibody levels:
Day 0:
Serum IgA anti-TcdA ≤435 units 14 64 74 47 2.01 0.61–6.56 3.04 0.78–12
Serum IgG anti-TcdA ≤408 units 14 36 75 53 0.49 0.15–1.59 0.49 0.13–1.76
Serum IgA anti-TcdB ≤1271 units 15 80 67 43 5.24 1.35–20 4.57 1.06–20
Serum IgG anti-TcdB ≤949 units 15 53 65 49 1.18 0.38–3.63 1.39 0.39–4.98
Serum TcdB-neutralizing capacity ≤0.44 7 57 33 49 1.42 0.27–7.34 1.03 0.17–6.16
Day 18–21:
Serum IgA anti-TcdA ≤366 units 14 71 76 46 2.93 0.84–10 6.06 1.40–26
Serum IgG anti-TcdA ≤460 units 14 64 75 48 1.95 0.60–6.37 3.31 0.85–13
Serum IgA anti-TcdB ≤1212 units 11 82 68 46 5.37 1.08–26 6.53 1.05–40
Serum IgG anti-TcdB <854 units 11 73 68 47 3.00 0.73–12 3.25 0.65–16
Serum TcdB-neutralizing capacity <0.60 4 75 33 52 2.82 0.27–30 4.50 0.25–81
Increase between day 0 and day 18–21:
Serum IgA anti-TcdA ≤ –42 units 14 57 74 49 1.41 0.45–4.64 2.08 0.57–7.62
Serum IgG anti-TcdA ≤ –22 units 14 79 74 45 4.56 1.17–18 5.35 1.22–23
Serum IgA anti-TcdB ≤ –419 units 11 36 44 55 0.48 0.12–1.87 0.50 0.10–2.49
Serum IgG anti-TcdB ≤ –362 units 11 55 43 49 1.26 0.33–4.75 0.93 0.18–4.77
CDI, Clostridium difficile infection; n, number of patients for whom information was available; Day 0, the day after completing 10 days of antibiotic treatment; OR, odds ratio; 95%
CI, 95% confidence interval; aOR, odds ratio adjusted for age >73 years and comorbidity other than immunocompromised status. Results printed in boldface have reached
statistical significance (p <0.05).
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(e.g. by faecal a1-antitrypsin clearance), may help to distinguish
between a causal relationship and confounding.
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